Horizon Pharma to be added to Nasdaq index

Deerfield-baseed Horizon Pharma has been selected for addition to the Nasdaq Biotechnology Index effective Monday.

The Nasdaq Biotechnology Index is designed to track the performance of a set of Nasdaq-listed securities classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. These companies must meet eligibility criteria that include a minimum market capitalization of $200 million and minimum average daily trading volume of 100,000 shares, among other requirements.

The Index Securities are evaluated semiannually in May and November and serve as the basis for the iShares Nasdaq Biotechnology Index Fund.